Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine.

× No keyword cloud information.

27 in total

1. In-vivo treatment with 5-azacytidine causes degeneration of central lymphatic organs and induces autoimmune disease in the chicken.

Authors: K Schauenstein; A Csordas; G Krömer; H Dietrich; G Wick
Journal: Int J Exp Pathol Date: 1991-06 Impact factor: 1.925

2. Capture and characterization of 5-aza-2'-deoxycytidine-treated C3H/10T1/2 cells prior to transformation.

Authors: S Rainier; A P Feinberg
Journal: Proc Natl Acad Sci U S A Date: 1988-09 Impact factor: 11.205

3. Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].

Authors: B J Braakhuis; G A van Dongen; M van Walsum; A Leyva; G B Snow
Journal: Invest New Drugs Date: 1988-12 Impact factor: 3.850

4. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.

Authors: A R Karpf; P W Peterson; J T Rawlins; B K Dalley; Q Yang; H Albertsen; D A Jones
Journal: Proc Natl Acad Sci U S A Date: 1999-11-23 Impact factor: 11.205

5. Bone loss in adult offspring induced by low-dose exposure to teratogens.

Authors: Arkady Torchinsky; Limor Mizrahi; Shoshana Savion; Ron Shahar; Vladimir Toder; Eugene Kobyliansky
Journal: J Bone Miner Metab Date: 2011-09-30 Impact factor: 2.626

6. 5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro.

Authors: J Bouchard; M C Walker; J M Leclerc; N Lapointe; R Beaulieu; L Thibodeau
Journal: Antimicrob Agents Chemother Date: 1990-02 Impact factor: 5.191

7. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.

Authors: Josephine Aimiuwu; Hongyan Wang; Ping Chen; Zhiliang Xie; Jiang Wang; Shujun Liu; Rebecca Klisovic; Alice Mims; William Blum; Guido Marcucci; Kenneth K Chan
Journal: Blood Date: 2012-04-19 Impact factor: 22.113

8. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors: Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal: Oncologist Date: 2016-04-18

Review 9. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors: William B Parker
Journal: Chem Rev Date: 2009-07 Impact factor: 60.622

10. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.

Authors: Benigno C Valdez; Xiaowen Tang; Yang Li; David Murray; Yan Liu; Uday Popat; Richard E Champlin; Borje S Andersson
Journal: Exp Hematol Date: 2018-08-10 Impact factor: 3.084